66 research outputs found
Synthesis and Biological Evaluation of Dantrolene-Like Hydrazide and Hydrazone Analogues as Multitarget Agents for Neurodegenerative Diseases
Dantrolene, a drug used for the management of malignant hyperthermia, had been recently evaluated for prospective repurposing as multitarget agent for neurodegenerative syndromes, including Alzheimer's disease (AD). Herein, twenty-one dantrolene-like hydrazide and hydrazone analogues were synthesized with the aim of exploring structure-activity relationships (SARs) for the inhibition of human monoamine oxidases (MAOs) and acetylcholinesterase (AChE), two well-established target enzymes for anti-AD drugs. With few exceptions, the newly synthesized compounds exhibited selectivity toward MAO B over either MAO A or AChE, with the secondary aldimine 9 and phenylhydrazone 20 attaining IC50 values of 0.68 and 0.81 ÎŒM, respectively. While no general SAR trend was observed with lipophilicity descriptors, a molecular simplification strategy allowed the main pharmacophore features to be identified, which are responsible for the inhibitory activity toward MAO B. Finally, further in vitro investigations revealed cell protection from oxidative insult and activation of carnitine/acylcarnitine carrier as concomitant biological activities responsible for neuroprotection by hits 9 and 20 and other promising compounds in the examined series
ADAMTS2 gene dysregulation in T/myeloid mixed phenotype acute leukemia.
Background: Mixed phenotype acute leukemias (MPAL) include acute leukemias with blasts that express antigens
of more than one lineage, with no clear evidence of myeloid or lymphoid lineage differentiation. T/myeloid (T/My)
MPAL not otherwise specified (NOS) is a rare leukemia that expresses both T and myeloid antigens, accounting
for less than 1% of all leukemias but 89% of T/My MPAL. From a molecular point of view, very limited data are
available on T/My MPAL NOS.
Case presentation: In this report we describe a T/My MPAL NOS case with a complex rearrangement involving
chromosomes 5 and 14, resulting in overexpression of the ADAM metallopeptidase with thrombospondin type 1
motif, 2 (ADAMTS2) gene due to its juxtaposition to the T cell receptor delta (TRD) gene segment.
Conclusion: Detailed molecular cytogenetic characterization of the complex rearrangement in the reported T/My
MPAL case allowed us to observe ADAMTS2 gene overexpression, identifying a molecular marker that may be useful
for monitoring minimal residual disease. To our knowledge, this is the first evidence of gene dysregulation due to a
chromosomal rearrangement in T/My MPAL NOS.
Keywords: Mixed phenotype acute leukemia, ADAMTS2, TRD, Complex chromosomal rearrangement, Promoter
swapping, Gene dysregulatio
Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia.
In this study we performed absolute quantification of the PML-RARA transcript by droplet digital polymerase chain reaction (ddPCR) in 76 newly diagnosed acute promyelocytic leukemia (APL) cases to verify the prognostic impact of the PML-RARA initial molecular burden. ddPCR analysis revealed that the amount of PML-RARA transcript at diagnosis in the group of patients who relapsed was higher than in that with continuous complete remission (CCR) (272 vs 89.2 PML-RARA copies/ng, p = 0.0004, respectively). Receiver operating characteristic analysis detected the optimal PML-RARA concentration threshold as 209.6 PML-RARA/ng (AUC 0.78; p < 0.0001) for discriminating between outcomes (CCR versus relapse). Among the 67 APL cases who achieved complete remission after the induction treatment, those with > 209.6 PML-RARA/ng had a worse relapse-free survival (p = 0.0006). At 5-year follow-up, patients with > 209.6 PML-RARA/ng had a cumulative incidence of relapse of 50.3% whereas 7.5% of the patients with suffered a relapse (p < 0.0001). Multivariate analysis identified the amount of PML-RARA before induction treatment as the sole independent prognostic factor for APL relapse.
Our results show that the pretreatment PML-RARA molecular burden could therefore be used to improve risk stratification in order to develop more individualized treatment regimens for high-risk APL cases
Hydroxy-propil-ÎČ-cyclodextrin inclusion complexes of two biphenylnicotinamide derivatives: Formulation and anti-proliferative activity evaluation in pancreatic cancer cell models
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies, with poor outcomes largely due to its unique microenvironment, which is responsible for the low response to drugs and drug-resistance phenomena. This clinical need led us to explore new therapeutic approaches for systemic PDAC treatment by the utilization of two newly synthesized biphenylnicotinamide derivatives, PTA73 and PTA34, with remarkable antitumor activity in an in vitro PDAC model. Given their poor water solubility, inclusion complexes of PTA34 and PTA73 in Hydroxy-Propil-ÎČ-Cyclodextrin (HP-ÎČ-CD) were prepared in solution and at the solid state. Complexation studies demonstrated that HP-ÎČ-CD is able to form stable hostâguest inclusion complexes with PTA34 and PTA73, characterized by a 1:1 apparent formation constant of 503.9 Mâ1 and 369.2 Mâ1, respectively (also demonstrated by the Job plot), and by an increase in aqueous solubility of about 150 times (from 1.95 ”g/mL to 292.5 ”g/mL) and 106 times (from 7.16 ”g/mL to 762.5 ”g/mL), in the presence of 45% w/v of HP-ÎČ-CD, respectively. In vitro studies confirmed the high antitumor activity of the complexed PTA34 and PTA73 towards PDAC cells, the strong G2/M phase arrest followed by induction of apoptosis, and thus their eligibility for PDAC therapy
Measurement of the angular correlation between the two gamma rays emitted in the radioactive decays of a Co source with two NaI(Tl) scintillator
We implemented a didactic experiment to study the angular correlation between
the two gamma rays emitted in typical Co radioactive decays. We used two
NaI(Tl) scintillators, already available in our laboratory, and a low-activity
Co source. The detectors were mounted on two rails, with the source at
their center. The first rail was fixed, while the second could be rotated
around the source. We performed several measurements by changing the angle
between the two scintillators in the range from to .
Dedicated background runs were also performed, removing the source from the
experimental setup. We found that the signal rate increases with the angular
separation between the two scintillators, with small discrepancies from the
theoretical expectations.Comment: 15 pages, 12 figure
Best practices in heterotrophic high-cell-density microalgal processes: achievements, potential and possible limitations
Microalgae of numerous heterotrophic genera (obligate or facultative) exhibit considerable metabolic versatility and flexibility but are currently underexploited in the biotechnological manufacturing of known plant-derived compounds, novel high-value biomolecules or enriched biomass. Highly efficient production of microalgal biomass without the need for light is now feasible in inexpensive, well-defined mineral medium, typically supplemented with glucose. Cell densities of more than 100Â gâlâ1 cell dry weight have been achieved with Chlorella, Crypthecodinium and Galdieria species while controlling the addition of organic sources of carbon and energy in fedbatch mode. The ability of microalgae to adapt their metabolism to varying culture conditions provides opportunities to modify, control and thereby maximise the formation of targeted compounds with non-recombinant microalgae. This review outlines the critical aspects of cultivation technology and current best practices in the heterotrophic high-cell-density cultivation of microalgae. The primary topics include (1) the characteristics of microalgae that make them suitable for heterotrophic cultivation, (2) the appropriate chemical composition of mineral growth media, (3) the different strategies for fedbatch cultivations and (4) the principles behind the customisation of biomass composition. The review confirms that, although fundamental knowledge is now available, the development of efficient, economically feasible large-scale bioprocesses remains an obstacle to the commercialisation of this promising technology
AZEPINO [4,3-b]INDOLE DERIVATIVES AS SELECTIVE INHIBITORS OF HUMAN BUTYRYLCHOLINESTERASE WITH PROTECTIVE EFFECTS AGAINST NMDA-INDUCED NEUROTOXICITY
Neurodegeneration in Alzheimerâs disease (AD), is a devastating disorder accounting for the majority of the dementias.1 Despite the advances achieved over the last two decades in the understanding of the pathogenic mechanisms underlying AD, only a few drugs are currently available, which include AChE
inhibitors (rivastigmine, galantamine, and donepezil), for the symptomatic relief of mild to moderate AD, and the N-methyl-D-aspartate receptor antagonist memantine.2 Previously, we reported the inhibitory activities of cholinesterases (ChEs) by a number of derivatives of annulated tetrahydroazocino-indoles, which preferentially inhibited AChE over BChE, with potency in the low micromolar range.3 New 6-substituted 3,4,5,6-tetrahydroazepino[4,3-b]indol-1(2H)-one (THAI) derivatives have been synthesized and evaluated for their activity as ChEsâ inhibitors. The most potent compounds have been identified among 6-(2-phenylethyl)-THAI derivatives, and in particular compounds 12b and 12d proved to be highly potent inhibitors of human BChE (IC50 = 13 and 1.8 nM, respectively), with 1000-fold selectivity over AChE. Structure-activity relationships revealed critical features (e.g., ring fusion [4,3-b], integrity of the lactam CONH function) and favorable physicochemical properties of the 6-(2-phenylethyl) group (i.e., optimal position, size and lipophilicity of phenyl substituents). Interestingly, 12b increased the viability of SH-SY5Y cells pre-treated with 250 ÎŒM NMDA, with significant effects (P<0.05) at concentrations ranging from 0.5 to 5 ÎŒM. These findings suggest that THAI can be used as a scaffold for developing new drug leads for the treatment of Alzheimer-type neurodegeneration syndrome
Insights into Diastereospecific Solvolysis of Peptidyl-ÎČ-Lactams: Combined Kinetic and Conformational Studies.
Preformulation studies and estimation of brain penetration for two alpidem analogues having anticonvulsivant activity
- âŠ